ECSP045254A - Derivados de indolilmaleimida - Google Patents
Derivados de indolilmaleimidaInfo
- Publication number
- ECSP045254A ECSP045254A EC2004005254A ECSP045254A ECSP045254A EC SP045254 A ECSP045254 A EC SP045254A EC 2004005254 A EC2004005254 A EC 2004005254A EC SP045254 A ECSP045254 A EC SP045254A EC SP045254 A ECSP045254 A EC SP045254A
- Authority
- EC
- Ecuador
- Prior art keywords
- diseases
- inflammatory
- damage
- syndrome
- shock
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 6
- 230000002757 inflammatory effect Effects 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 3
- 230000001404 mediated effect Effects 0.000 abstract 3
- 208000011580 syndromic disease Diseases 0.000 abstract 3
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 230000001154 acute effect Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 208000030090 Acute Disease Diseases 0.000 abstract 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 201000004624 Dermatitis Diseases 0.000 abstract 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 206010012442 Dermatitis contact Diseases 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 abstract 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 abstract 1
- 208000002705 Glucose Intolerance Diseases 0.000 abstract 1
- 208000009329 Graft vs Host Disease Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 206010022680 Intestinal ischaemia Diseases 0.000 abstract 1
- 206010067125 Liver injury Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 206010063837 Reperfusion injury Diseases 0.000 abstract 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 abstract 1
- 206010038934 Retinopathy proliferative Diseases 0.000 abstract 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 abstract 1
- 206010040070 Septic Shock Diseases 0.000 abstract 1
- 206010049771 Shock haemorrhagic Diseases 0.000 abstract 1
- 208000031709 Skin Manifestations Diseases 0.000 abstract 1
- 208000037913 T-cell disorder Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 206010044541 Traumatic shock Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 206010046851 Uveitis Diseases 0.000 abstract 1
- 206010053648 Vascular occlusion Diseases 0.000 abstract 1
- 208000002029 allergic contact dermatitis Diseases 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 238000002399 angioplasty Methods 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000037976 chronic inflammation Diseases 0.000 abstract 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 201000011190 diabetic macular edema Diseases 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 230000001434 glomerular Effects 0.000 abstract 1
- 231100000234 hepatic damage Toxicity 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 230000006749 inflammatory damage Effects 0.000 abstract 1
- 208000001875 irritant dermatitis Diseases 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 206010023332 keratitis Diseases 0.000 abstract 1
- 201000010666 keratoconjunctivitis Diseases 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 230000008818 liver damage Effects 0.000 abstract 1
- 231100000516 lung damage Toxicity 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 206010028417 myasthenia gravis Diseases 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 abstract 1
- 201000009104 prediabetes syndrome Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 208000008742 seborrheic dermatitis Diseases 0.000 abstract 1
- 230000036303 septic shock Effects 0.000 abstract 1
- 230000035939 shock Effects 0.000 abstract 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1
- 210000001685 thyroid gland Anatomy 0.000 abstract 1
- 230000009529 traumatic brain injury Effects 0.000 abstract 1
- 230000003966 vascular damage Effects 0.000 abstract 1
- 208000021331 vascular occlusion disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
Abstract
Se proporcionan compuestos de la fórmula (I), los cuales son útiles en el tratamiento y/o prevención de enfermedades o desórdenes mediados por linfocitos T y/o PKC, por ejemplo, rechazo agudo o crónico de alo- o xenoinjertos de órgano o tejido, enfermedades de injerto contra huésped, ateroscleorisis, oclusión vascular debido a daño vascular tal como angioplastía, restenosis, obesidad, síndrome X, tolerancia dañada a glucosa, síndrome de ovario poliquístico, hipertensión, falla cardiaca, enfermedad pulmonar obstructiva crónica, enfermedades del CNS tales como enfermedad de Alzheimer o esclerosis lateral amiotrófica, cáncer, enfermedades infecciosas tales como SIDA, choque séptico o síndrome de dificultad respiratoria en adultos, daño por isquemia/reperfusión, por ejemplo, infarto al miocardio, choque, isquemia de intestinos, falla renal o choque hemorrágico, o choque traumático, por ejemplo, daño traumático del cerebro. Los compuestos de (I) también son útiles en el tratamiento y/o prevención de enfermedades o desórdenes inflamatorios agudos o crónicos mediados por célula T o enfermedades autoinmunes, por ejemplo, artritis reumatoide, osteoartritis, lupus sistémico eritematoso, tiroides de Hashimoto, esclerosis múltiple,miastenia grave, diabetes de tipo I o II y los deórdeenes asociados con las mismas, por ejemplo, antipatía, retinopatía proliferativa diabética, edema macular diabético, nefropatía, neuropatía y síndrome de Dawn, enfermedades respiratorias tales como asma o daño inflamatorio del pulmón, daño inflamatorio del hígado, daño inflamatorio glomerular, manifestaciones cutáneas de enfermedades o desórdenes inmunológicamente mediados, enfermedades inflamatorias e hiperproliferativas de la piel (tales como psoriasis, dermatitis atópica, dermatitis alérgica de contacto, dermatitis irritante de contacto y otras dermatitis eczematosas, dermatitis seborréica), enfermedades inflamatorias de los ojos, por ejemplo, síndrome de Sjegren, queratoconjuntivitis o uveítis, enfermedad inflamatoria del intestino, enfermedad de Crohn o colitis ulcerativa.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0207729A GB0207729D0 (en) | 2002-04-03 | 2002-04-03 | Organic compounds |
| GB0303323A GB0303323D0 (en) | 2003-02-13 | 2003-02-13 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP045254A true ECSP045254A (es) | 2004-09-28 |
Family
ID=28676503
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2004005254A ECSP045254A (es) | 2002-04-03 | 2004-08-27 | Derivados de indolilmaleimida |
| EC2008005254A ECSP085254A (es) | 2002-04-03 | 2008-12-12 | Derivados de indolilmaleimida |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2008005254A ECSP085254A (es) | 2002-04-03 | 2008-12-12 | Derivados de indolilmaleimida |
Country Status (26)
| Country | Link |
|---|---|
| US (5) | US20050119274A1 (es) |
| EP (1) | EP1490355B1 (es) |
| JP (1) | JP4247125B2 (es) |
| KR (2) | KR100942329B1 (es) |
| CN (1) | CN100351251C (es) |
| AR (1) | AR039209A1 (es) |
| AT (1) | ATE517888T1 (es) |
| AU (1) | AU2003224031B2 (es) |
| BR (1) | BR0308979A (es) |
| CA (1) | CA2477774C (es) |
| CO (1) | CO5611127A2 (es) |
| CY (1) | CY1111982T1 (es) |
| DK (1) | DK1490355T3 (es) |
| EC (2) | ECSP045254A (es) |
| IL (1) | IL163892A0 (es) |
| MX (1) | MXPA04009632A (es) |
| MY (1) | MY137566A (es) |
| NO (1) | NO329166B1 (es) |
| NZ (1) | NZ535613A (es) |
| PE (1) | PE20040079A1 (es) |
| PL (1) | PL213480B1 (es) |
| PT (1) | PT1490355E (es) |
| RU (1) | RU2340610C2 (es) |
| SI (1) | SI1490355T1 (es) |
| TW (2) | TW200918046A (es) |
| WO (1) | WO2003082859A1 (es) |
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6645970B2 (en) * | 2000-11-07 | 2003-11-11 | Novartis Ag | Indolylmaleimide derivatives |
| TW200918046A (en) * | 2002-04-03 | 2009-05-01 | Novartis Ag | Indolylmaleimide derivatives |
| GB0303319D0 (en) * | 2003-02-13 | 2003-03-19 | Novartis Ag | Organic compounds |
| EP1608317B1 (en) | 2003-03-25 | 2012-09-26 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| EP1625122A1 (en) | 2003-05-14 | 2006-02-15 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| US7790736B2 (en) | 2003-08-13 | 2010-09-07 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| JP2007509185A (ja) * | 2003-10-27 | 2007-04-12 | ノバルティス アクチエンゲゼルシャフト | βアミロイド産生および／または凝集と関係がある神経障害および血管障害の処置のためのインドリル−ピロールジオン誘導体 |
| US7582631B2 (en) | 2004-01-14 | 2009-09-01 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| ATE391127T1 (de) | 2004-01-19 | 2008-04-15 | Novartis Pharma Gmbh | Indolylmaleimidderivate |
| US20070232658A1 (en) * | 2004-04-08 | 2007-10-04 | Jurgen Wagner | Protein Kinase C Inhibitors for the Treatment of Autoimmune Diseases and of Transplant Rejiction |
| GB0410713D0 (en) | 2004-05-13 | 2004-06-16 | Novartis Ag | Organic compounds |
| GB0504203D0 (en) * | 2005-03-01 | 2005-04-06 | Novartis Ag | Organic compounds |
| JP4747364B2 (ja) * | 2005-04-04 | 2011-08-17 | 独立行政法人産業技術総合研究所 | 紫外線皮膚炎抑止剤およびアトピー性皮膚炎抑止剤 |
| GB0507918D0 (en) | 2005-04-19 | 2005-05-25 | Novartis Ag | Organic compounds |
| WO2006117212A2 (en) | 2005-05-04 | 2006-11-09 | Develogen Aktiengesellschaft | Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders |
| GB0511060D0 (en) | 2005-05-31 | 2005-07-06 | Novartis Ag | Organic compounds |
| WO2007006533A2 (en) * | 2005-07-11 | 2007-01-18 | Novartis Ag | Indolylmaleimide derivatives |
| EP1749523A1 (en) * | 2005-07-29 | 2007-02-07 | Neuropharma, S.A. | GSK-3 inhibitors |
| WO2007025177A2 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
| JP5027137B2 (ja) | 2005-09-14 | 2012-09-19 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼ阻害剤の投与 |
| KR101368988B1 (ko) | 2005-09-16 | 2014-02-28 | 다케다 야쿠힌 고교 가부시키가이샤 | 디펩티딜 펩티다제 억제제 |
| EP2377530A3 (en) | 2005-10-21 | 2012-06-20 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
| KR101749388B1 (ko) | 2005-10-26 | 2017-06-20 | 노파르티스 아게 | Ｉｌ-1베타 화합물의 신규 용도 |
| EP1942879A1 (en) | 2005-10-31 | 2008-07-16 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| ES2481671T3 (es) | 2005-11-21 | 2014-07-31 | Novartis Ag | Inhibidores de mTOR en el tratamiento de tumores endocrinos |
| GB0601744D0 (en) | 2006-01-27 | 2006-03-08 | Novartis Ag | Organic compounds |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| GB0605691D0 (en) * | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic Compounds |
| EP2021000A2 (en) | 2006-05-09 | 2009-02-11 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| GB0613162D0 (en) * | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic compounds |
| WO2008024734A2 (en) * | 2006-08-23 | 2008-02-28 | Novartis Ag | Use of pkc inhibitors in particular indolylmaleimide derivatives in ocular diseases |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
| CN101583358A (zh) * | 2006-12-07 | 2009-11-18 | 诺瓦提斯公司 | Pkc抑制剂在移植中的用途 |
| MX2009006533A (es) | 2006-12-19 | 2009-06-26 | Novartis Ag | Derivados de indolil-maleimida como inhibidores de cinasa. |
| CN101754682B (zh) | 2007-05-16 | 2014-11-12 | 布里格姆妇女医院 | 突触核蛋白病的治疗 |
| CA2947947C (en) | 2007-05-29 | 2018-03-06 | Novartis Ag | New indications for anti-il-1-beta therapy |
| US7943163B2 (en) | 2007-08-22 | 2011-05-17 | Response Scientific, Inc. | Medical food or nutritional supplement, method of manufacturing same, and method of managing diabetes |
| US20090054513A1 (en) * | 2007-08-22 | 2009-02-26 | Response Scientific, Inc. | Method of managing blood glucose levels, insulin levels and/or insulin receptor functionality in individuals with diabetes, polycystic ovarian syndrome and/or alzheimer's disease |
| ES2379673T3 (es) | 2007-11-08 | 2012-04-30 | Novartis Ag | Firmas de expresión génica para nefropatía de aloingerto crónica/esclerosante |
| PE20091522A1 (es) * | 2007-12-21 | 2009-10-29 | Novartis Ag | Composicion farmaceutica solida que contiene 3-(1.h-indol-3-il)-4-[2-(4-metil-piperazin-1-il)-quinazolin-4-il]-quinazolin-4-il]-pirrol-2,5-diona |
| US8268834B2 (en) | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
| ES2331451B1 (es) * | 2008-06-30 | 2010-10-21 | Consejo Superior De Investigaciones Cientificas (Csic) | Inmunosupresor basado en la interrupcion de la interaccion tcr-nck. |
| US8475790B2 (en) | 2008-10-06 | 2013-07-02 | Bristol-Myers Squibb Company | Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases |
| DE202008014557U1 (de) | 2008-10-27 | 2009-03-12 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Therapeutische Verwendung |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| CN101671329B (zh) * | 2009-06-17 | 2012-11-07 | 东华大学 | 3-氨基醇取代的吲哚马来酰亚胺化合物、其制备和应用 |
| US9752191B2 (en) | 2009-07-09 | 2017-09-05 | The Scripps Research Institute | Gene expression profiles associated with chronic allograft nephropathy |
| TWI535440B (zh) * | 2009-10-26 | 2016-06-01 | Ｌｇ生命科學有限公司 | 包括吲哚化合物之醫藥組成物 |
| US8791100B2 (en) | 2010-02-02 | 2014-07-29 | Novartis Ag | Aryl benzylamine compounds |
| KR101461767B1 (ko) | 2010-03-30 | 2014-11-13 | 노파르티스 아게 | 만성 활성 ｂ-세포-수용체 신호전달이 있는 ｂ-세포 림프종의 치료를 위한 ｐｋｃ 억제제 |
| UA112517C2 (uk) | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
| US8785648B1 (en) | 2010-08-10 | 2014-07-22 | The Regents Of The University Of California | PKC-epsilon inhibitors |
| WO2012027328A2 (en) | 2010-08-23 | 2012-03-01 | Board Of Regents, The University Of Texas System | Anti-ox40 antibodies and methods of using the same |
| CZ305457B6 (cs) | 2011-02-28 | 2015-09-30 | Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. | Pyrimidinové sloučeniny inhibující tvorbu oxidu dusnatého a prostaglandinu E2, způsob výroby a použití |
| UY34072A (es) * | 2011-05-17 | 2013-01-03 | Novartis Ag | Derivados sustituidos de indol |
| PH12013502524A1 (en) | 2011-06-27 | 2014-01-27 | Novartis Ag | Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives |
| CN103732596B (zh) | 2011-07-08 | 2016-06-01 | 诺华股份有限公司 | 吡咯并嘧啶衍生物 |
| JP2014530851A (ja) | 2011-10-21 | 2014-11-20 | ノバルティスアーゲー | Ｐｉ３ｋモジュレータとしてのキナゾリン誘導体 |
| AP2014007680A0 (en) | 2011-12-02 | 2014-06-30 | Novartis Ag | Anti-1L-beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease |
| AP3849A (en) | 2011-12-15 | 2016-09-30 | Novartis Ag | Use of inhibitors of the activity or function of pi3k |
| EP2794594A1 (en) | 2011-12-22 | 2014-10-29 | Novartis AG | Quinoline derivatives |
| PL2794600T3 (pl) | 2011-12-22 | 2018-06-29 | Novartis Ag | Pochodne 2,3-dihydro-benzo[1,4]oksazyny i powiązane związki jako inhibitory kinazy fosfoinozytydu-3 (PI3K) do leczenia np. reumatoidalnego zapalenia stawów |
| US20150284364A1 (en) | 2012-11-07 | 2015-10-08 | Nicole Bieri | Substituted indole derivatives |
| TW201422625A (zh) | 2012-11-26 | 2014-06-16 | Novartis Ag | 二氫－吡啶并－□衍生物之固體形式 |
| US9446043B2 (en) | 2012-11-29 | 2016-09-20 | Novartis Ag | Pharmaceutical combinations |
| AU2014209141B2 (en) | 2013-01-24 | 2018-05-10 | Palvella Therapeutics, Inc. | Compositions for transdermal delivery of mTOR inhibitors |
| WO2014128612A1 (en) | 2013-02-20 | 2014-08-28 | Novartis Ag | Quinazolin-4-one derivatives |
| WO2014174478A1 (en) | 2013-04-26 | 2014-10-30 | Novartis Ag | Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor |
| CA2920059A1 (en) | 2013-09-22 | 2015-03-26 | Calitor Sciences, Llc | Substituted aminopyrimidine compounds and methods of use |
| KR101630806B1 (ko) | 2013-11-14 | 2016-06-16 | 대한민국 | 돼지의 초위성체 마커를 이용한 개체식별 방법 |
| US9512084B2 (en) | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
| US9394281B2 (en) | 2014-03-28 | 2016-07-19 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| BR112016024533A8 (pt) | 2014-04-24 | 2021-03-30 | Novartis Ag | derivados de amino pirazina como inibidores de fosfatidilinositol 3-cinase ou sal, seu uso, e composição e combinação farmacêuticas |
| BR112016023967A2 (pt) | 2014-04-24 | 2017-08-15 | Novartis Ag | derivados de pirazina como inibidores de fosfatidilinositol 3-cinase |
| EA201692140A1 (ru) | 2014-04-24 | 2017-04-28 | Новартис Аг | Производные аминопиридина в качестве ингибиторов фосфатидилинозитол 3-киназы |
| US11104951B2 (en) | 2014-05-22 | 2021-08-31 | The Scripps Research Institute | Molecular signatures for distinguishing liver transplant rejections or injuries |
| US10443100B2 (en) | 2014-05-22 | 2019-10-15 | The Scripps Research Institute | Gene expression profiles associated with sub-clinical kidney transplant rejection |
| EP3146077A4 (en) | 2014-05-22 | 2018-05-02 | The Scripps Research Institute | Tissue molecular signatures of kidney transplant rejections |
| EP3180003B1 (en) | 2014-07-01 | 2022-01-12 | The Regents of the University of California | Pkc-epsilon inhibitors |
| JO3589B1 (ar) | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
| WO2016179517A1 (en) | 2015-05-07 | 2016-11-10 | Agenus Inc. | Anti-ox40 antibodies and methods of use thereof |
| EP3347097B1 (en) | 2015-09-11 | 2021-02-24 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora |
| WO2017096179A1 (en) | 2015-12-02 | 2017-06-08 | Agenus Inc. | Antibodies and methods of use thereof |
| MA46770A (fr) | 2016-11-09 | 2019-09-18 | Agenus Inc | Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation |
| CN110520097B (zh) | 2017-01-06 | 2023-10-27 | 帕尔维拉治疗股份有限公司 | Mtor抑制剂的无水组合物及其使用方法 |
| WO2018175340A1 (en) | 2017-03-20 | 2018-09-27 | Sienna Biopharmaceuticals, Inc. | Reduced exposure conjugates modulating therapeutic targets |
| WO2018175302A1 (en) | 2017-03-20 | 2018-09-27 | Sienna Biopharmaceuticals, Inc. | Polymer conjugates targeting c-src with reduced exposure |
| EP3710006A4 (en) | 2017-11-19 | 2021-09-01 | Sunshine Lake Pharma Co., Ltd. | SUBSTITUTED HETEROARYL COMPOUNDS AND METHOD OF USING |
| KR102737185B1 (ko) | 2018-01-20 | 2024-12-05 | 선샤인 레이크 파르마 컴퍼니 리미티드 | 치환된 아미노피리미딘 화합물 및 이의 사용 방법 |
| CN110551103B (zh) * | 2018-05-30 | 2022-08-23 | 北京大学深圳研究生院 | 一种jak3选择性抑制剂 |
| EP3817743A4 (en) | 2018-07-02 | 2022-07-06 | Palvella Therapeutics, Inc. | ANHYDROUS COMPOSITIONS OF MTOR INHIBITORS AND METHODS OF USE |
| CN121471152A (zh) | 2019-05-23 | 2026-02-06 | 诺华股份有限公司 | Btk抑制剂的晶型 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL89167A (en) * | 1988-02-10 | 1994-02-27 | Hoffmann La Roche | Substituted pyrroles, their manufacture and pharmaceutical compositions containing them |
| MC2096A1 (fr) * | 1989-02-23 | 1991-02-15 | Hoffmann La Roche | Pyrroles substitues |
| EP1120414A1 (en) * | 1998-07-30 | 2001-08-01 | Japan Tobacco Inc. | Disubstituted maleimide compounds and medicinal utilization thereof |
| US6281356B1 (en) | 1999-12-22 | 2001-08-28 | Hoffmann-La Roche Inc. | Substituted pyrroles |
| BR0112965A (pt) * | 2000-07-27 | 2003-07-08 | Hoffmann La Roche | Derivados de 3-indolil-4-fenil-1h-pirrol-2,5-diona como inibidores de glocogênio sintase cinase-3beta |
| ES2332770T3 (es) * | 2000-11-07 | 2010-02-12 | Novartis Ag | Derivados de indolilmaleimida como inhibidores de la proteina quinasa c. |
| US6645970B2 (en) * | 2000-11-07 | 2003-11-11 | Novartis Ag | Indolylmaleimide derivatives |
| TW200918046A (en) * | 2002-04-03 | 2009-05-01 | Novartis Ag | Indolylmaleimide derivatives |
| JP2007509185A (ja) * | 2003-10-27 | 2007-04-12 | ノバルティス アクチエンゲゼルシャフト | βアミロイド産生および／または凝集と関係がある神経障害および血管障害の処置のためのインドリル−ピロールジオン誘導体 |
-
2003
- 2003-04-01 TW TW097141220A patent/TW200918046A/zh unknown
- 2003-04-01 AR ARP030101128A patent/AR039209A1/es active IP Right Grant
- 2003-04-01 PE PE2003000330A patent/PE20040079A1/es not_active Application Discontinuation
- 2003-04-01 TW TW092107388A patent/TWI324064B/zh not_active IP Right Cessation
- 2003-04-02 AT AT03720413T patent/ATE517888T1/de active
- 2003-04-02 BR BR0308979-7A patent/BR0308979A/pt not_active IP Right Cessation
- 2003-04-02 AU AU2003224031A patent/AU2003224031B2/en not_active Expired
- 2003-04-02 RU RU2004132203/04A patent/RU2340610C2/ru not_active IP Right Cessation
- 2003-04-02 PL PL371322A patent/PL213480B1/pl unknown
- 2003-04-02 MX MXPA04009632A patent/MXPA04009632A/es active IP Right Grant
- 2003-04-02 DK DK03720413.8T patent/DK1490355T3/da active
- 2003-04-02 SI SI200332053T patent/SI1490355T1/sl unknown
- 2003-04-02 IL IL16389203A patent/IL163892A0/xx unknown
- 2003-04-02 EP EP03720413A patent/EP1490355B1/en not_active Expired - Lifetime
- 2003-04-02 US US10/510,027 patent/US20050119274A1/en not_active Abandoned
- 2003-04-02 WO PCT/EP2003/003470 patent/WO2003082859A1/en not_active Ceased
- 2003-04-02 JP JP2003580325A patent/JP4247125B2/ja not_active Expired - Lifetime
- 2003-04-02 NZ NZ535613A patent/NZ535613A/en not_active IP Right Cessation
- 2003-04-02 PT PT03720413T patent/PT1490355E/pt unknown
- 2003-04-02 KR KR1020077007917A patent/KR100942329B1/ko not_active Expired - Fee Related
- 2003-04-02 CN CNB038053438A patent/CN100351251C/zh not_active Expired - Lifetime
- 2003-04-02 KR KR1020047015591A patent/KR100886521B1/ko not_active Expired - Fee Related
- 2003-04-02 CA CA2477774A patent/CA2477774C/en not_active Expired - Lifetime
- 2003-04-02 MY MYPI20031225A patent/MY137566A/en unknown
-
2004
- 2004-08-27 EC EC2004005254A patent/ECSP045254A/es unknown
- 2004-09-15 CO CO04091784A patent/CO5611127A2/es active IP Right Grant
- 2004-10-26 NO NO20044613A patent/NO329166B1/no not_active IP Right Cessation
-
2006
- 2006-10-12 US US11/546,690 patent/US7358253B2/en not_active Expired - Lifetime
- 2006-10-12 US US11/546,693 patent/US7235555B2/en not_active Expired - Lifetime
-
2007
- 2007-10-25 US US11/977,565 patent/US20080108628A1/en not_active Abandoned
-
2008
- 2008-02-21 US US12/034,675 patent/US7534808B2/en not_active Expired - Lifetime
- 2008-12-12 EC EC2008005254A patent/ECSP085254A/es unknown
-
2011
- 2011-10-27 CY CY20111101021T patent/CY1111982T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP045254A (es) | Derivados de indolilmaleimida | |
| KR101368988B1 (ko) | 디펩티딜 펩티다제 억제제 | |
| KR100250176B1 (ko) | 벤젠술폰아미드 유도체 및 이의 제조방법 | |
| HU227475B1 (en) | Nitrogenous heterocyclic carboxamide derivatives or salts thereof and antiviral agents containing them | |
| BRPI0314830B8 (pt) | derivados de azol-pirimidina fundida | |
| WO1998027108A3 (en) | New amide compounds and their use as nitric oxide synthase inhibitors | |
| MY133479A (en) | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | |
| CA2474578A1 (en) | Novel pyridin- and pyrimidin-derivatives | |
| TW200512210A (en) | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | |
| CY1108713T1 (el) | Συντηγμενες ενωσεις προς αναστολη του υποδοχεα βανιλλοϊδους υποτυπου 1 (vr1) | |
| DE602005013822D1 (de) | Cycloalkylaminderivate | |
| US20220073555A1 (en) | Galectin-3 inhibiting c-glycosides | |
| US12304902B2 (en) | Hydroxyheterocycloalkane-carbamoyl derivatives | |
| WO2008113760A3 (en) | Arylsulphonyglycine derivatives as suppressors of the interaction of glycogen phosphorylase a with the gl subunit of glycogen-associated protein phosphatase 1 (ppl) for the treatment of metabolic disorders, particulary diabetes | |
| WO2005092856A8 (en) | Tetrahydrocarbazoles and derivatives | |
| JP2004527513A5 (es) | ||
| US5708013A (en) | Pyridine derivative and therapeutic agent for ulcer comprising the same | |
| ES2890552T3 (es) | Compuestos de pirimidina sustituidos y su uso como inhibidores de SYK | |
| ES2776462T3 (es) | Derivados del ácido 3-(6-cloro-3-oxo-3,4-dihidro-(2H)-1,4-benzoxazin-4-il)propanoico y su uso como inhibidores de KMO | |
| TW200631580A (en) | Substituted benzoquinolizine derivatives | |
| WO2009005838A3 (en) | Process for the preparation of a non-corrosive base solution and methods of using same | |
| JP5366803B2 (ja) | 脳梗塞治療剤 | |
| CN102124010A (zh) | 具有血管舒张活性的硝酸异山梨酯 | |
| WO2005121153A1 (ja) | 縮合ピリミジン誘導体、及びキサンチンオキシダーゼ阻害剤 | |
| DE2945248A1 (de) | Cephem-verbindungen, verfahren zu ihrer herstellung und sie enthaltende antibakterielle pharmazeutische mittel |